XML 32 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Note 1 - Organization and Nature of Business (Details Textual)
2 Months Ended 3 Months Ended 6 Months Ended
Jul. 27, 2016
$ / shares
shares
Jun. 27, 2016
$ / shares
shares
Apr. 15, 2016
USD ($)
$ / shares
shares
Mar. 02, 2016
USD ($)
shares
Feb. 13, 2016
Feb. 12, 2016
USD ($)
$ / shares
shares
Apr. 15, 2016
USD ($)
$ / shares
shares
Jun. 30, 2016
$ / shares
shares
Jun. 30, 2016
USD ($)
$ / shares
shares
Jun. 30, 2015
USD ($)
Jun. 26, 2016
$ / shares
shares
Dec. 31, 2015
$ / shares
shares
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | New Options [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           1,807,744            
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares           $ 0.87            
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | Predecessor Options [Member]                        
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross           17,784            
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares           $ 1.25            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           295,945            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 1.25            
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member] | New Warrants [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           3,403,367            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 1.03            
Protagenic Therapeutics Inc [Member] | Series B Preferred Stock [Member]                        
Common Shares Exchanged for Preferred Shares           (6,612,838)            
Preferred Stock, Par or Stated Value Per Share | $ / shares           $ 0.000001            
Protagenic Therapeutics Inc [Member] | Placement Agent Warrants [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           127,346            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 1.25            
Protagenic Therapeutics Inc [Member] | Predecessor Warrants [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           295,945            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 1.25            
Protagenic Therapeutics Inc [Member] | Private Placement [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           3,403,367            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 1.05            
Protagenic Therapeutics Inc [Member]                        
Business Acquisition, Conversion of Stock, Ratio           1            
Business Combination, Stock Warrant Conversion Ratio           1            
Stock Issued During Period, Shares, Conversion of Series A Preferred Stock to Series B Preferred Stock           297,468            
Series B Preferred Stock [Member] | Placement Agent Warrants [Member] | Private Placement [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     127,346       127,346          
Class of Warrant or Right, Value of Securities Called by Warrants or Rights | $     $ 146,641       $ 146,641          
Series B Preferred Stock [Member] | Predecessor Warrants [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           295,945            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 1.25            
Warrants Issued for Settlement and Conversion of Debt | $           $ 340,784            
Series B Preferred Stock [Member] | Private Placement [Member] | Including Conversion of Principal and Interest [Member]                        
Proceeds from Issuance of Private Placement | $             5,135,575          
Proceeds From Issuance of Private Placement, Net of Issuance Costs | $             $ 4,783,438          
Series B Preferred Stock [Member] | Private Placement [Member]                        
Class of Warrant or Right, Number of Securities Called by Warrants or Rights           423,291            
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares           $ 1.25            
Shares Issued, Price Per Share | $ / shares           $ 1.25            
Stock Issued During Period, Value, New Issues | $           $ 3,468,750            
Stock Issued During Period, Shares, New Issues     420,260 913,200     4,108,460          
Proceeds from Issuance of Convertible Preferred Stock | $     $ 525,325 $ 1,141,500                
Proceeds from Issuance of Private Placement | $             $ 4,635,575          
Proceeds From Issuance of Private Placement, Net of Issuance Costs | $             $ 4,283,438          
Series B Preferred Stock [Member] | Reverse Stock Split [Member] | Subsequent Event [Member]                        
Stockholders' Equity Note, Stock Split, Conversion Ratio 15,463.7183                      
Series B Preferred Stock [Member]                        
Preferred Stock, Par or Stated Value Per Share | $ / shares               $ 0.000001 $ 0.000001     $ 0.000001
Proceeds from Issuance of Convertible Preferred Stock | $                 $ 4,283,437    
Preferred Stock, Shares Authorized               18,000,000 18,000,000     18,000,000
Placement Agent Warrants [Member] | Private Placement [Member]                        
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares     $ 1.25       $ 1.25          
Common Stock [Member]                        
Stock Issued During Period, Shares, Reverse Stock Split, Post-split           25,867            
Stock Issued During Period, Value, New Issues | $                      
Stock Issued During Period, Value, Conversion of Convertible Securities | $                 $ 6      
Stock Issued During Period, Shares, New Issues                      
Debt Principal Conversion to Predecessor Warrants [Member]                        
Debt Conversion, Original Debt, Amount | $           $ 665,000            
Debt Interest Conversion to Predecessor Warrants [Member]                        
Debt Conversion, Original Debt, Amount | $           35,000            
Conversion of Outstanding Stockholder Debt [Member] | Predecessor's Stockholder [Member]                        
Stock Issued During Period, Value, Conversion of Convertible Securities | $           150,000            
Conversion of Outstanding Stockholder Debt [Member] | Chairman and Board Member Garo H. Armen [Member]                        
Stock Issued During Period, Value, Conversion of Convertible Securities | $           $ 350,000            
Momspot LLC [Member]                        
Noncontrolling Interest, Ownership Percentage by Parent           51.00%            
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners           49.00%            
Interest Ownership Split Off         51.00%              
Investors in the Private Offering [Member]                        
Number of Common Stock Held As Converted Basis           2,775,000            
Private Placement [Member] | Commissions [Member]                        
Payments of Stock Issuance Costs | $     $ 159,183                  
Private Placement [Member] | Expense Allowance [Member]                        
Payments of Stock Issuance Costs | $     15,000                  
Private Placement [Member] | Legal and Miscellaneous Fees [Member]                        
Payments of Stock Issuance Costs | $     $ 266,727                  
Reverse Stock Split [Member]                        
Stockholders' Equity Note, Stock Split, Conversion Ratio   15,463.7183                    
Subsequent Event [Member] | Stock Conversion from Series B Preferred Stock to Common Stock [Member]                        
Convertible Preferred Stock, Shares Issued upon Conversion 1                      
Conversion of Stock, Shares Converted 11,018,766                      
Conversion of Stock, Shares Issued 11,018,766                      
Subsequent Event [Member]                        
Preferred Stock, Par or Stated Value Per Share | $ / shares $ 0.000001                      
Common Stock, Par or Stated Value Per Share | $ / shares $ 0.0001                      
Stock Shares Authorized 120,000,000                      
Common Stock, Shares Authorized 100,000,000                      
Preferred Stock, Shares Authorized 20,000,000                      
Stock Conversion from Series B Preferred Stock to Common Stock [Member]                        
Convertible Preferred Stock, Shares Issued upon Conversion   1                    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross                 1,301,084      
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares               $ 1.25 $ 1.25      
Common Stock, Par or Stated Value Per Share | $ / shares   $ 0.0001       $ 0.0001   $ 0.0001 $ 0.0001   $ 0.000001 $ 0.0001
Number of Wholly-Owned Subsidiaries Split Off         29              
Stock Issued During Period, Value, New Issues | $                 $ 4,761,797      
Stock Issued During Period, Value, Conversion of Convertible Securities | $                 75,265      
Warrants Issued for Settlement and Conversion of Debt | $                 $ 340,784    
Common Stock, Shares Authorized   100,000,000           100,000,000 100,000,000   100,000,000,000 100,000,000
Preferred Stock, Shares Authorized   20,000,000                 5,000,000,000